Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Neurosci Lett
2010 Oct 15;4833:167-72. doi: 10.1016/j.neulet.2010.08.001.
Show Gene links
Show Anatomy links
Altered GABA(A) receptor subunit expression and pharmacology in human Angelman syndrome cortex.
Roden WH
,
Peugh LD
,
Jansen LA
.
???displayArticle.abstract???
The neurodevelopmental disorder Angelman syndrome is most frequently caused by deletion of the maternally derived chromosome 15q11-q13 region, which includes not only the causative UBE3A gene, but also the beta(3)-alpha(5)-gamma(3) GABA(A) receptor subunit gene cluster. GABAergic dysfunction has been hypothesized to contribute to the occurrence of epilepsy and cognitive and behavioral impairments in this condition. In the present study, analysis of GABA(A) receptor subunit expression and pharmacology was performed in cerebral cortex from four subjects with Angelman syndrome and compared to that from control tissue. The membrane fraction of frozen postmortem neocortical tissue was isolated and subjected to quantitative Western blot analysis. The ratios of beta(3)/beta(2) and alpha(5)/alpha(1) subunit protein expression in Angelman syndrome cortex were significantly decreased when compared with controls. An additional membrane fraction was injected into Xenopus oocytes, resulting in incorporation of the brain membrane vesicles with their associated receptors into the oocytecellular membrane. Two-electrode voltage-clamp analysis of GABA(A) receptor currents was then performed. Studies of GABA(A) receptor pharmacology in Angelman syndrome cortex revealed increased current enhancement by the alpha(1)-selective benzodiazepine-site agonist zolpidem and by the barbiturate phenobarbital, while sensitivity to current inhibition by zinc was decreased. GABA(A) receptor affinity and modulation by neurosteroids were unchanged. This shift in GABA(A) receptor subunit expression and pharmacology in Angelman syndrome is consistent with impaired extrasynaptic but intact to augmented synaptic cortical GABAergic inhibition, which could contribute to the epileptic, behavioral, and cognitive phenotypes of the disorder.
???displayArticle.pubmedLink???
20692323
???displayArticle.pmcLink???PMC3233535 ???displayArticle.link???Neurosci Lett ???displayArticle.grants???[+]
Asahina,
[(11)C]flumazenil positron emission tomography analyses of brain gamma-aminobutyric acid type A receptors in Angelman syndrome.
2008, Pubmed
Asahina,
[(11)C]flumazenil positron emission tomography analyses of brain gamma-aminobutyric acid type A receptors in Angelman syndrome.
2008,
Pubmed
Belelli,
The influence of subunit composition on the interaction of neurosteroids with GABA(A) receptors.
2002,
Pubmed
,
Xenbase
Benke,
Distribution, prevalence, and drug binding profile of gamma-aminobutyric acid type A receptor subtypes differing in the beta-subunit variant.
1994,
Pubmed
Burgard,
Properties of recombinant gamma-aminobutyric acid A receptor isoforms containing the alpha 5 subunit subtype.
1996,
Pubmed
DeLorey,
Mice lacking the beta3 subunit of the GABAA receptor have the epilepsy phenotype and many of the behavioral characteristics of Angelman syndrome.
1998,
Pubmed
Fradley,
Differential contribution of GABA(A) receptor subtypes to the anticonvulsant efficacy of benzodiazepine site ligands.
2007,
Pubmed
Glykys,
Activation of GABAA receptors: views from outside the synaptic cleft.
2007,
Pubmed
Hadingham,
Role of the beta subunit in determining the pharmacology of human gamma-aminobutyric acid type A receptors.
1993,
Pubmed
,
Xenbase
Handforth,
Pharmacologic evidence for abnormal thalamocortical functioning in GABA receptor beta3 subunit-deficient mice, a model of Angelman syndrome.
2005,
Pubmed
Hogart,
15q11-13 GABAA receptor genes are normally biallelically expressed in brain yet are subject to epigenetic dysregulation in autism-spectrum disorders.
2007,
Pubmed
Holopainen,
Decreased binding of [11C]flumazenil in Angelman syndrome patients with GABA(A) receptor beta3 subunit deletions.
2001,
Pubmed
Homanics,
Mice devoid of gamma-aminobutyrate type A receptor beta3 subunit have epilepsy, cleft palate, and hypersensitive behavior.
1997,
Pubmed
Jansen,
Impaired maturation of cortical GABA(A) receptor expression in pediatric epilepsy.
2010,
Pubmed
Jansen,
GABA(A) receptor properties in catastrophic infantile epilepsy.
2008,
Pubmed
,
Xenbase
Jay,
Puppet-like syndrome of Angelman: a pathologic and neurochemical study.
1991,
Pubmed
Kralic,
Molecular and pharmacological characterization of GABA(A) receptor alpha1 subunit knockout mice.
2002,
Pubmed
Krasowski,
A deficit of functional GABA(A) receptors in neurons of beta 3 subunit knockout mice.
1998,
Pubmed
Lalande,
Molecular epigenetics of Angelman syndrome.
2007,
Pubmed
Miledi,
Expression of functional neurotransmitter receptors in Xenopus oocytes after injection of human brain membranes.
2002,
Pubmed
,
Xenbase
Minassian,
Angelman syndrome: correlations between epilepsy phenotypes and genotypes.
1998,
Pubmed
Möhler,
Specific GABA(A) circuits in brain development and therapy.
2004,
Pubmed
Odano,
Decrease in benzodiazepine receptor binding in a patient with Angelman syndrome detected by iodine-123 iomazenil and single-photon emission tomography.
1996,
Pubmed
Palma,
Abnormal GABAA receptors from the human epileptic hippocampal subiculum microtransplanted to Xenopus oocytes.
2005,
Pubmed
,
Xenbase
Pelc,
Epilepsy in Angelman syndrome.
2008,
Pubmed
Pirker,
Increased expression of GABA(A) receptor beta-subunits in the hippocampus of patients with temporal lobe epilepsy.
2003,
Pubmed
Ramadan,
GABA(A) receptor beta3 subunit deletion decreases alpha2/3 subunits and IPSC duration.
2003,
Pubmed
Raol,
Long-term effects of diazepam and phenobarbital treatment during development on GABA receptors, transporters and glutamic acid decarboxylase.
2005,
Pubmed
Reynolds,
Sedation and anesthesia mediated by distinct GABA(A) receptor isoforms.
2003,
Pubmed
Samaco,
Epigenetic overlap in autism-spectrum neurodevelopmental disorders: MECP2 deficiency causes reduced expression of UBE3A and GABRB3.
2005,
Pubmed
Sinkkonen,
Mouse models of Angelman syndrome, a neurodevelopmental disorder, display different brain regional GABA(A) receptor alterations.
2003,
Pubmed
Thibert,
Epilepsy in Angelman syndrome: a questionnaire-based assessment of the natural history and current treatment options.
2009,
Pubmed
Thompson,
Barbiturate interactions at the human GABAA receptor: dependence on receptor subunit combination.
1996,
Pubmed
,
Xenbase
Valente,
Epilepsy in patients with angelman syndrome caused by deletion of the chromosome 15q11-13.
2006,
Pubmed
Williams,
Angelman syndrome 2005: updated consensus for diagnostic criteria.
2006,
Pubmed
